This Small Cannabis Company Made $32 Million in Nine Months

If you want to buy a cannabis stock with the right mix of explosive upside and legitimacy, then don’t miss this one.

Oh, the conundrum of cannabis investing…

Yes, cannabis is legal (by prescription) in 33 U.S. states.

Eleven states allow for recreational use, and major market states, including New York, New Jersey and Illinois will (most likely) be joining the party soon.

As an investor, you’re looking at the historic end to  cannabis prohibition, which could move $50 billion per year from the black market to legal sales.

At the same time, you’re faced with multitudes of small competitors – most of which have no real revenues – carrying cash burn rates that model early-stage biotech startups.

Which companies will win? Which will lose? And most importantly, are any of them even worthy of your investment dollars?

Allow me to answer all those questions by introducing your newest Small Cap Blaster: Trulieve Cannabis (OTC: TCNNF).

The company offers a suite of Trulieve-branded products, including nasal sprays, capsules, concentrates, syringes, cannabis flowers, topical creams, tinctures and vape cartridges. As of January 14, it operates 24 dispensaries in Florida. The company also takes orders online and by phone.

Here’s why it’s a winner.

In the first nine months of 2018, Trulieve made a profit of $32 million. Yes, it is one of the few cannabis companies operating in the black (or I should say… “operating in the green” – sorry, I couldn’t help it).

As you know, early investors are always looking for a perfect balance between major upside speculation and an element of safety. In most cases, these two characteristics aren’t found together. With Trulieve Cannabis, this is the closest you’ll come to having both of these rare metrics working for you.

Action Plan: With today’s Trulieve Cannabis pullback, I’d consider dipping a toe into the water.

Yours in smart speculation,

Bryan Bottarelli

facebook twitter
A Look Inside the War Room...

If you don’t have a premeditated sell discipline – and the vast majority of investors don’t.

Popular Posts